All In Biotech

Drug Trial Radar · NCT05367778

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10370 Monotherapy in Patients with Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

176

Planned (sponsor's estimate)

Start

Jun 3, 2022

Primary completion

Apr 30, 2025

Study completion Apr 30, 2026

Sponsor

Sponsor type
Industry
First posted
May 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.

Conditions

  • Advanced Solid Tumor

Interventions

  • HS-10370Drug

    HS-10370 will be administered orally once daily in a continuous regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia:To determine the maximum tolerated dose (MTD)Time frame: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (28 days).
  2. 2. Phase Ib/II: To evaluate clinical activity/efficacy of HS-10370 by assessment of objective response rateTime frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.